AgomAb Therapeutics N.V. American Depositary Shares (AGMB) Stock

About AgomAb Therapeutics N.V. American Depositary Shares

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.

AgomAb Therapeutics N.V. American Depositary Shares is led by CEO Tim Knotnerus, employs 57 people, headquartered in BE, publicly traded since 2024.

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) stock trades at $14.90 with a market capitalization of $733.79M. The stock is valued at a price-to-earnings (P/E) ratio of -10.49, price-to-book of 4.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.75 and $17.82, and currently trades 16.4% below its 52-week high.

On profitability, AgomAb Therapeutics N.V. American Depositary Shares generates a return on equity (ROE) of -45.90%, return on capital employed of -43.87%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: agomab.com